AUS
NZ
UK
CA
USA
IND
Highlights
- Wellnex Life defers $2.95M payment to 1Q25 for its Pain Away acquisition.
- Planned listing on the London Stock Exchange to support debt retirement and expansion.
- LSE listing anticipated to enhance liquidity for international growth.
Wellnex Life Ltd (ASX:WNX) has decided to defer its $2.95 million payment to 365 Health, originally scheduled for late October, until January 20, 2025. The decision comes as the company prepares for a significant milestone: its planned listing on the London Stock Exchange (LSE), anticipated in early 2025. Wellnex, which recently acquired the popular topical pain relief brand Pain Away, aims to align this payment with its LSE listing to streamline its strategic and financial objectives.
This deferment allows Wellnex to focus on its upcoming LSE debut, a move the company views as instrumental for its long-term goals. By listing on the LSE Main Board, Wellnex intends to enhance its ability to retire outstanding debts, including the deferred payment to 365 Health and existing convertible notes, which are central to the company’s financial strategy. The listing is also expected to support its ambitions for international expansion by facilitating access to a broader base of UK-based institutional and sophisticated investors.
In a statement released Tuesday, Wellnex highlighted that this strategic listing on the LSE would enable it to raise necessary liquidity to advance its business goals. The need for additional liquidity has become a focal point for the company, especially after closing the September quarter with a cash balance of $300,000. The LSE listing is expected to open doors to new growth opportunities and financial resources, helping the company accelerate its expansion plans.
Interestingly, Wellnex’s move echoes similar steps taken by other Australian healthcare companies, such as Telix Pharmaceuticals Ltd (ASX:TLX), which had earlier considered listing on the NASDAQ but later chose not to proceed. Unlike Telix, however, Wellnex appears resolute in its LSE plans, with preparations underway to publish a prospectus for the listing later this month.
Wellnex’s focus on expanding its presence in international markets aligns with its broader vision of becoming a global healthcare provider. The upcoming LSE listing is expected to position the company favorably, both in terms of financial flexibility and access to a wider investor base. The deferred payment to 365 Health appears to be a strategic choice to balance Wellnex’s immediate financial needs with its longer-term growth aspirations.
Currently, Wellnex shares trade at 66.5 cents on the ASX, as the company looks ahead to its potential transformation through the LSE listing and the financial opportunities it hopes to unlock.
